Portage BiotechPRTG
Market Cap: $10.6M
About: Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
Employees: 7
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0.48% more ownership
Funds ownership: 10.84% [Q1] → 11.32% (+0.48%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
8% less funds holding
Funds holding: 24 [Q1] → 22 (-2) [Q2]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
54% less capital invested
Capital invested by funds: $1.21M [Q1] → $558K (-$650K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for PRTG.